OTLK — Outlook Therapeutics Share Price
0.000.00%
Last trade - 00:00- $182.18m
- $208.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.15 | n/a | n/a | n/a | n/a | 0.24 | 13.1 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Directors
- Ralph Thurman CHM (72)
- C. Russell Trenary PRE (64)
- Lawrence Kenyon CFO (56)
- Terry Dagnon COO (60)
- Joel Prieve SVP
- Jeff Evanson OTH (53)
- Gerd Auffarth IND (57)
- Julian Gangolli IND (64)
- Yezan Haddadin IND (46)
- Kurt Hilzinger IND (61)
- Andong Huang IND (25)
- Faisal Sukhtian IND (37)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 22nd, 2015
- Public Since
- June 13th, 2016
- No. of Shareholders
- 80
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 22,298,542
- Address
- 485 Route 1 South, Building F, Suite 320, ISELIN, 08830
- Web
- https://outlooktherapeutics.com/
- Phone
- +1 6096193990
- Contact
- Jenene Thomas
- Auditors
- KPMG LLP
Upcoming Events for OTLK
Q3 2024 Outlook Therapeutics Inc Earnings Release
Similar to OTLK
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Outlook Therapeutics share price?
As of Today at 19:16 UTC, shares in Outlook Therapeutics are trading at $8.17. This share price information is delayed by 15 minutes.
How has the Outlook Therapeutics share price performed this year?
Shares in Outlook Therapeutics last closed at $8.17 and the price had moved by -65.67% over the past 365 days. In terms of relative price strength the Outlook Therapeutics share price has underperformed the S&P500 Index by -71.43% over the past year.
What are the analyst and broker recommendations for Outlook Therapeutics?
The overall consensus recommendation for Outlook Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Outlook Therapeutics dividend yield?
Outlook Therapeutics does not currently pay a dividend.
Does Outlook Therapeutics pay a dividend?
Outlook Therapeutics does not currently pay a dividend.
When does Outlook Therapeutics next pay dividends?
Outlook Therapeutics does not currently pay a dividend.
How do I buy Outlook Therapeutics shares?
To buy shares in Outlook Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Outlook Therapeutics?
As of the previous close price of $8.17, shares in Outlook Therapeutics had a market capitalisation of $182.18m.
Where are Outlook Therapeutics shares listed?
Here are the trading details for Outlook Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: OTLK
What kind of share is Outlook Therapeutics?
Based on an overall assessment of its quality, value and momentum Outlook Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Outlook Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Outlook Therapeutics is $39.91. That is 388.49% above the last closing price of $8.17.
Analysts covering Outlook Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.28 for the next financial year.
What is the trend in the Outlook Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Outlook Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -28.03%.
As of the last closing price of $8.17, shares in Outlook Therapeutics were trading -34.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Outlook Therapeutics PE Ratio?
The Outlook Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Outlook Therapeutics?
Outlook Therapeutics' management team is headed by:
- Ralph Thurman - CHM
- C. Russell Trenary - PRE
- Lawrence Kenyon - CFO
- Terry Dagnon - COO
- Joel Prieve - SVP
- Jeff Evanson - OTH
- Gerd Auffarth - IND
- Julian Gangolli - IND
- Yezan Haddadin - IND
- Kurt Hilzinger - IND
- Andong Huang - IND
- Faisal Sukhtian - IND